Literature DB >> 10837939

The significance of radiotherapy treatment duration in intracranial ependymoma.

A C Paulino1, B C Wen.   

Abstract

PURPOSE: To determine if radiation therapy treatment duration has an impact on the outcome of intracranial ependymoma. METHODS AND MATERIALS: From 1965 to 1997, 34 patients with intracranial ependymoma were seen and treated with postoperative radiotherapy (RT). There were 26 male and 8 female patients with a median age of 14 years (range, 18 months to 60 years). Tumor location was infratentorial in 23 (67.6%) and supratentorial in 11 (32.4%). Pathology was low-grade in 25 (73.5%) and high-grade in 9 (26.5%). Two (5.9%) patients had M+ disease at initial diagnosis. Gross total resection was achieved in 12 (35.3%), subtotal resection in 19 (55. 9%), and biopsy alone in 3 (8.8%). Median RT dose to the primary site was 5400 cGy (range, 4500 cGy to 6600 cGy). The entire neuraxis was treated in 14 (41.2%), whole brain in 9 (26.5%), and the primary site alone in 11 (32.4%). Median radiotherapy treatment duration was 43 days (range, 26 to 122 days). Patients treated with craniospinal RT were more likely to have treatment duration of > or =50 days. Median follow-up was 108 months (range, 24 to 252 months).
RESULTS: The 5-, 10-, and 15-year overall survival rates were 71.5%, 63.3%, and 55.4%. Local control rates at 5, 10, and 15 years were 61.8%, 57.7%, and 57.7%. For patients with RT treatment duration <50 days, the 5-, 10-, and 15-year overall survivals were 85.5%, 78.9%, and 65.7% whereas for those with treatment duration > or = 50 days, the corresponding rates were 45.5%, 36.4%, and 36.4% (p = 0.01, log-rank test). Local control rate at 5, 10, and 15 years was 70.6% for patients with RT treatment duration <50 days and 45.5%, 36.4%, and 36.4% for patients with RT treatment duration > or =50 days (p = 0.05, log-rank test). Age, gender, tumor location, tumor grade, degree of surgical resection, RT volume, and RT dose (4500-5399 cGy vs. 5400-6600 cGy) were not found to have a statistically significant impact on overall survival, disease-free survival, or local control. The most common site of failure was local, found in 13 (38.2%) patients. Three patients also had spinal failure in addition to a primary site failure. There were no isolated nonprimary site brain or spine failures.
CONCLUSIONS: Radiation therapy treatment duration is an important prognostic factor for survival and local control with patients having treatment duration <50 days having a better outcome than those with treatment duration > or =50 days. Because the overwhelming site of failure was local, we recommend local field irradiation in patients with M0 disease.

Entities:  

Mesh:

Year:  2000        PMID: 10837939     DOI: 10.1016/s0360-3016(99)00535-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

1.  Adult intracranial WHO grade II ependymomas: long-term outcome and prognostic factor analysis in a series of 114 patients.

Authors:  Philippe Metellus; Jacques Guyotat; Olivier Chinot; Anne Durand; Marylin Barrie; Roch Giorgi; Anne Jouvet; Dominique Figarella-Branger
Journal:  Neuro Oncol       Date:  2010-05-19       Impact factor: 12.300

2.  Outcome of postoperative radiation therapy for pediatric intracranial ependymoma: a single-institution review.

Authors:  Rawee Ruangkanchanasetr; Thiti Swangsilpa; Putipun Puataweepong; Mantana Dhanachai; Ake Hansasuta; Atthaporn Boongird; Nongnuch Sirachainan; Suradej Hongeng
Journal:  Childs Nerv Syst       Date:  2019-06-16       Impact factor: 1.475

3.  Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy.

Authors:  Sunanda Pejavar; Mei-Yin Polley; Sarah Rosenberg-Wohl; Sravana Chennupati; Michael D Prados; Mitchel S Berger; Anuradha Banerjee; Nalin Gupta; Daphne Haas-Kogan
Journal:  J Neurooncol       Date:  2011-08-09       Impact factor: 4.130

4.  Recurrent pituitary ependymoma: a complex clinical problem.

Authors:  Rosie Belcher; Harvinder S Chahal; Jane Evanson; Farhad Afshar; Silvia Marino; Ashley B Grossman
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

Review 5.  Childhood ependymoma: a systematic review of treatment options and strategies.

Authors:  Jacques Grill; Chastagner Pascal; Kalifa Chantal
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

6.  Intracranial ependymomas in adult patients: analyses of prognostic factors.

Authors:  J Guyotat; F Signorelli; S Desme; D Frappaz; G Madarassy; M Fevre Montange; A Jouvet; Ph Bret
Journal:  J Neurooncol       Date:  2002-12       Impact factor: 4.130

Review 7.  Biology and management of ependymomas.

Authors:  Jing Wu; Terri S Armstrong; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2016-03-28       Impact factor: 12.300

Review 8.  WHO Grade II and III supratentorial hemispheric ependymomas in adults: case series and review of treatment options.

Authors:  Toba N Niazi; Elizabeth M Jensen; Randy L Jensen
Journal:  J Neurooncol       Date:  2008-11-01       Impact factor: 4.130

9.  Retrospective analysis of treatment outcome of pediatric ependymomas in Korea: analysis of Korean multi-institutional data.

Authors:  Yeon-Joo Kim; Joo-Young Kim; Do Hoon Lim; Hyeon Jin Park; Jungnam Joo; Ki Woong Sung; Hyung Jin Shin; Seung-Ki Kim; Ji Hoon Phi; Il Han Kim; Kyung Duk Park; Seung-do Ahn; Jinhong Jung; Young-Shin Ra; Young Sin Rha; Dong-Seok Kim; Chang-Ok Suh
Journal:  J Neurooncol       Date:  2013-03-06       Impact factor: 4.130

10.  Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis.

Authors:  Amol J Ghia; Anita Mahajan; Pamela K Allen; Terri S Armstrong; Frederick F Lang; Mark R Gilbert; Paul D Brown
Journal:  J Neurooncol       Date:  2013-10-02       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.